PIK3CA and vulva cancer: In contrast, most evidence for biomarker-guided targeted drugs against cervical, vaginal and vulvar cancer, such as mTOR/PIK3CA and PARP inhibitor-based therapies, stemmed from preclinical data, as most of the drugs suggested by the MTBs had only sporadically been tested in clinical settings for these diseases.